ReviewFrontiers in immunology2024
Case report: Systemic sclerosis during neoadjuvant therapy for breast cancer in a 59-year-old woman.
Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The efficacy and safety of tocilizumab in juvenile localised scleroderma patients: a retrospective cohort study in Eastern China.Advances in rheumatology (London, England) · 2025Article
- Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis (SSc) is an autoimmune connective tissue disease with skin fibrosis being the first and most common manifestation. Patients with SSc have a higher risk of developing malignant tumors than the general population. However, the sequence and underlying mechanisms linking SSc to malignancy remain controversial. This article presents the case of a 59-year-old woman who was diagnosed with SSc after developing skin fibrosis during neoadjuvant therapy for breast cancer. Despite aggressive antitumor treatments, including targeted therapy, SSc did not improve and progressed rapidly with increasing dermatofibrosis. Remarkably, the SSc entered remission following the cessation of antitumor therapy. Additionally, we reviewed the literature on SSc and malignant tumors, examined their relationship, and discussed key points regarding their identification and potential for adverse drug reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.